Amanta Healthcare
95.73
-2.65(-2.69%)
Market Cap₹371.71 Cr
PE Ratio25.04
IndustryHealthcare
Company Performance:
1D-2.69%
1M-11.82%
6M-31.56%
1Y-32.47%
5Y-32.47%
View Company Insightsright
More news about Amanta Healthcare
14Nov 25
Amanta Healthcare Allocates Rs 3,030 Crore from IPO Proceeds for Expansion
Amanta Healthcare Limited has used Rs 3,030.02 lakhs from its IPO proceeds for the quarter ending September 30, 2025. The funds were primarily used for capital expenditure at its Gujarat facility, including manufacturing equipment and civil construction. The company still has Rs 9,569.98 lakhs available for further planned expansions. Amanta plans to commence a SteriPort Manufacturing Line in January 2026 and an SVP Manufacturing Line in January 2027, both located in Hariyala, Kheda, Gujarat. For Q2 FY2026, the company reported a total income from operations of Rs 7,095.80 lakhs and a net profit after tax of Rs 120.76 lakhs.
 no imag found
12Nov 25
Amanta Healthcare Reports Fund Utilization Deviation and Q2 FY2026 Financial Results
Amanta Healthcare Limited disclosed a deviation in IPO fund utilization due to GST payment changes, adjusting issue expenses and reducing general corporate purpose expenses. The company's Q2 FY2026 results show revenue growth to Rs. 7,088.73 lakhs, but a decrease in net profit to Rs. 120.75 lakhs compared to Q2 FY2025. Half-year performance improved with revenue at Rs. 13,619.44 lakhs and net profit at Rs. 471.47 lakhs. Balance sheet highlights include increased total assets of Rs. 48,831.55 lakhs and improved cash position of Rs. 9,196.41 lakhs as of September 30, 2025.
 no imag found
12Nov 25
Amanta Healthcare Reports Q2 Profit, Completes IPO Listing
Amanta Healthcare Limited reported Q2 FY2026 results with total income of Rs. 7,095.80 lakhs and net profit of Rs. 207.80 lakhs. For H1 FY2026, total income was Rs. 13,850.45 lakhs with net profit of Rs. 185.50 lakhs. The company completed its IPO, issuing 10 million shares at Rs. 126 each, raising Rs. 12,600 lakhs. Listing occurred on September 9, 2025, on BSE and NSE. IPO proceeds are allocated for new manufacturing lines and corporate purposes, with Rs. 3,030.02 lakhs utilized so far. PriceWaterhouseCoopers provided an unmodified review opinion on the financial results.
 no imag found
Amanta Healthcare
95.73
-2.65
(-2.69%)
1 Year Returns:-32.47%
Industry Peers
Sun Pharmaceutical
1,801.60
(-1.30%)
Divis Laboratories
6,071.00
(-3.36%)
Torrent Pharmaceuticals
4,390.00
(-1.26%)
Dr Reddys Laboratories
1,292.30
(-2.02%)
Cipla
1,314.70
(-0.72%)
Lupin
2,314.90
(-1.80%)
Zydus Life Science
905.90
(-1.20%)
Mankind Pharma
2,138.90
(-3.13%)
Aurobindo Pharma
1,296.50
(-1.17%)
Alkem Laboratories
5,355.50
(-1.63%)